Table 2 Univariable and multivariable analyses of recurrence-free survival of patients with EGFR-Mt lung cancer

Age (≥65)

0.95

0.64–1.44

0.829

Gender (Male)

1.21

0.82–1.81

0.333

Smoking history (+)

1.43

0.96–2.12

0.079

Side (left)

1.48

0.99–2.23

0.058

CEA (> 10 ng/ml)

1.85

1.14–3.00

0.013

CT tumor size (> 4.0 cm)

1.31

0.85–2.02

0.224

Consolidation size (> 4.0 cm)

1.43

0.90–2.27

0.127

GGO (−)

1.48

0.98–2.24

0.066

PET maxSUV (≥6.0)

2.21

1.48–3.28

< 0.001

Surgical procedure (segmentectomy)

0.46

0.11–1.88

0.282

Invasive lepidic adenocarcinoma

0.61

0.30–1.26

0.182

Invasive acinar adenocarcinoma

0.78

0.52–1.17

0.225

Invasive papillary adenocarcinoma

1.29

0.85–1.95

0.225

Invasive solid adenocarcinoma

1.64

0.83–3.27

0.156

Invasive micropapillary adenocarcinoma

1.18

0.52–2.71

0.690

High grade adenocarcinoma

1.54

0.91–2.61

0.104

Lymphatic vessel invasion (+)

2.02

1.36–3.00

< 0.001

Blood vessel invasion (+)

2.96

1.86–4.73

< 0.001

Pleural invasion (+)

1.10

0.73–1.66

0.645

Nodal metastasis (+)

2.71

1.77–4.14

< 0.001

Lepidic component (+)

1.05

0.56–1.97

0.877

Solid component (+)

1.02

0.69–1.52

0.916

Micropapillary component (+)

1.34

0.89–2.03

0.161

Adjuvant chemotherapy (%)

1.02

0.69–1.53

0.906

EGFR exon 21L858R

1.01

0.68–1.50

0.962